{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:50:12Z","timestamp":1792533012311,"version":"4.5.0"},"reference-count":72,"publisher":"BMJ","issue":"16","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2025,2,11]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>\n                    Implantation of drug-eluting stents (DESs) remains central to percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) and chronic coronary syndromes (CCS). DES platforms, polymers and drugs have evolved significantly to improve deliverability and safety, now being typically thin-strut with a compact layer of biocompatible or bioresorbable polymer, or no polymer at all. Ultra-thin-strut DESs push this concept further, and in some studies perform better than conventional DES, but may recoil in challenging settings such as chronic total occlusion PCI. Stent implantation has also progressed, with greater attention to lesion preparation and poststenting optimisation, increased use of intracoronary imaging helping to recognise and remedy issues. In parallel, antithrombotic therapy for patients undergoing PCI has advanced considerably, with reliable P2Y\n                    <jats:sub>12<\/jats:sub>\n                    inhibition now possible with the newest agents. As well as progress in controlling other thrombotic risk factors such as hyperlipidaemia, hypertension and diabetes, these developments have contributed to reducing thrombotic risk. As well as preventing stent thrombosis, antithrombotic therapy can reduce the risk of non-PCI-related thrombotic events, not only in the coronary tree but also in the cerebral and peripheral circulation, however it increases bleeding risk. Twelve months of dual antiplatelet therapy (DAPT) after PCI for ACS (and 6 months after PCI for CCS) remains the default recommended strategy, but given reliable P2Y\n                    <jats:sub>12<\/jats:sub>\n                    inhibition, good control of ischaemic risk factors and a minimally thrombogenic stent design and deployment, it is rational that earlier de-escalation to monotherapy, particularly with ticagrelor, is often appropriate, reserving longer-duration DAPT for those with highest ischaemic risk but where bleeding risk is not high. A body of trial evidence now supports this. As well as earlier de-escalation of DAPT, future developments in PCI might include increased use of \u2018leave nothing behind\u2019 strategies and further pharmacological options for optimisation of ischaemic risk factors.\n                  <\/jats:p>","DOI":"10.1136\/heartjnl-2024-324744","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T13:20:48Z","timestamp":1741094448000},"page":"753-762","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Evolution of coronary stents: innovations, antithrombotic strategies and future directions"],"prefix":"10.1136","volume":"111","clinical-trial-number":[{"clinical-trial-number":"nct04436978","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05955365","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05125276","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04360720","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7822-8852","authenticated-orcid":false,"given":"William A E","family":"Parker","sequence":"first","affiliation":[{"name":"Cardiovascular Research Unit, The University of Sheffield, Sheffield, England, UK"},{"name":"Department of Cardiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"2025121416150579000_111.16.753.1","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2025121416150579000_111.16.753.2","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2025121416150579000_111.16.753.3","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-316914"},{"key":"2025121416150579000_111.16.753.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)95756-9"},{"key":"2025121416150579000_111.16.753.5","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldt009"},{"key":"2025121416150579000_111.16.753.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198703193161201"},{"key":"2025121416150579000_111.16.753.7","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(94)90675-0"},{"key":"2025121416150579000_111.16.753.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199408253310802"},{"key":"2025121416150579000_111.16.753.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012843"},{"key":"2025121416150579000_111.16.753.10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv203"},{"key":"2025121416150579000_111.16.753.11","doi-asserted-by":"publisher","DOI":"10.17925\/HI.2020.14.1.34"},{"key":"2025121416150579000_111.16.753.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2018.07.040"},{"key":"2025121416150579000_111.16.753.13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.108.832048"},{"key":"2025121416150579000_111.16.753.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2016.12.002"},{"key":"2025121416150579000_111.16.753.15","doi-asserted-by":"publisher","DOI":"10.1007\/s12928-019-00613-w"},{"key":"2025121416150579000_111.16.753.16","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.a2014.0004"},{"key":"2025121416150579000_111.16.753.17","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2014-000064","article-title":"First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients","volume":"1","author":"Eliano Pio","year":"2014","journal-title":"Open Heart"},{"key":"2025121416150579000_111.16.753.18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab894"},{"key":"2025121416150579000_111.16.753.19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab790"},{"key":"2025121416150579000_111.16.753.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2024.01.018"},{"key":"2025121416150579000_111.16.753.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2016.10.017"},{"key":"2025121416150579000_111.16.753.22","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-316745"},{"key":"2025121416150579000_111.16.753.23","article-title":"Trends and impact of intravascular ultrasound and optical coherence tomography on percutaneous coronary intervention for myocardial infarction","volume":"45","author":"Park","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2025121416150579000_111.16.753.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216607"},{"key":"2025121416150579000_111.16.753.25","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2019-315090"},{"key":"2025121416150579000_111.16.753.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2015.06.020"},{"key":"2025121416150579000_111.16.753.27","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV9I1A10"},{"key":"2025121416150579000_111.16.753.28","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/suaa165"},{"key":"2025121416150579000_111.16.753.29","doi-asserted-by":"publisher","DOI":"10.4244\/EIJY14M09_11"},{"key":"2025121416150579000_111.16.753.30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.072009"},{"key":"2025121416150579000_111.16.753.31","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-307858"},{"key":"2025121416150579000_111.16.753.32","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp041"},{"key":"2025121416150579000_111.16.753.33","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034790"},{"key":"2025121416150579000_111.16.753.34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32236-4"},{"key":"2025121416150579000_111.16.753.35","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2017.1280601"},{"key":"2025121416150579000_111.16.753.36","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae233"},{"key":"2025121416150579000_111.16.753.37","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2086515","article-title":"Trajectories of Blood Pressure in Patients with Established Coronary Artery Disease over 20 years","volume":"2022","author":"Jankowski","year":"2022","journal-title":"Int J Hypertens"},{"key":"2025121416150579000_111.16.753.38","unstructured":"Office of National Statistics . Adult smoking habits in Great Britain. 2024."},{"key":"2025121416150579000_111.16.753.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01616-7"},{"key":"2025121416150579000_111.16.753.40","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamacardio.2024.0133","article-title":"Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Systematic Review and Patient-Level Meta-Analysis","volume":"9","author":"Valgimigli","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2025121416150579000_111.16.753.41","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab607"},{"key":"2025121416150579000_111.16.753.42","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.123.013302","article-title":"Drug-Coated Balloons in the Management of Coronary Artery Disease","volume":"17","author":"Korjian","year":"2024","journal-title":"Circ Cardiovasc Interv"},{"key":"2025121416150579000_111.16.753.43","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-57261"},{"key":"2025121416150579000_111.16.753.44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01594-0"},{"key":"2025121416150579000_111.16.753.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2023.01.007"},{"key":"2025121416150579000_111.16.753.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2023.09.010"},{"key":"2025121416150579000_111.16.753.47","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV7SKA21"},{"key":"2025121416150579000_111.16.753.48","article-title":"Coronary Drug-Coated Balloons for De Novo and In-Stent Restenosis Indications","volume":"2","author":"Giacoppo","year":"2023","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"2025121416150579000_111.16.753.49","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-024-03709-1","article-title":"Randomized evaluation of 5-month Ticagrelor monotherapy after 1-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with drug-coated balloons: REC-CAGEFREE II trial rationale and design","volume":"24","author":"Gao","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"key":"2025121416150579000_111.16.753.50","first-page":"199","article-title":"Bioresorbable coronary scaffolds are ready for a comeback: pros and cons","volume":"19","author":"Stone","year":"2023","journal-title":"EuroIntervention"},{"key":"2025121416150579000_111.16.753.51","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.066720"},{"key":"2025121416150579000_111.16.753.52","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0525-0"},{"key":"2025121416150579000_111.16.753.53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1907096"},{"key":"2025121416150579000_111.16.753.54","doi-asserted-by":"crossref","unstructured":"Azzahhafi J , van den Broek WWA , Chan Pin Yin D , et al . Real-World Implementation of a Genotype-Guided P2Y12 Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients. JACC Cardiovasc Interv 2024. doi:10.1016\/j.jcin.2024.06.020","DOI":"10.1093\/eurheartj\/ehae666.3340"},{"key":"2025121416150579000_111.16.753.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.03.470"},{"key":"2025121416150579000_111.16.753.56","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100047","article-title":"Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery","volume":"1","author":"Bhatt","year":"2022","journal-title":"NEJM Evid"},{"key":"2025121416150579000_111.16.753.57","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.123.064473"},{"key":"2025121416150579000_111.16.753.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.04.051"},{"key":"2025121416150579000_111.16.753.59","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae617"},{"key":"2025121416150579000_111.16.753.60","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32249-3"},{"key":"2025121416150579000_111.16.753.61","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31877-X"},{"key":"2025121416150579000_111.16.753.62","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02197-9"},{"key":"2025121416150579000_111.16.753.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.02.014"},{"key":"2025121416150579000_111.16.753.64","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32467-X"},{"key":"2025121416150579000_111.16.753.65","doi-asserted-by":"crossref","unstructured":"de Winter RJ , Katagiri Y , Asano T , et al . A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial. Lancet 2018;391. doi:10.1016\/S0140-6736(17)33103-3","DOI":"10.1016\/S0140-6736(17)33103-3"},{"key":"2025121416150579000_111.16.753.66","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-18-00358"},{"key":"2025121416150579000_111.16.753.67","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31858-0"},{"key":"2025121416150579000_111.16.753.68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908419"},{"key":"2025121416150579000_111.16.753.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.08.1038"},{"key":"2025121416150579000_111.16.753.70","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.7580"},{"key":"2025121416150579000_111.16.753.71","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.066943"},{"key":"2025121416150579000_111.16.753.72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00473-2"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2024-324744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:15:21Z","timestamp":1765757721000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2024-324744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":72,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,7,28]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/heartjnl-2024-324744"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2024-324744","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]}}}